Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624013 · ClinicalTrials.gov registry record · Phase 4
Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.
A Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00624013: Completed Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
NCT00624013 is a Phase 4 study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 89 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00624013, a Phase 4 study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
This proposed study will test the following hypothesis: Treating depression in Hispanics and African Americans with diabetes will improve their HbA1c and quality of life while on intervention and six months after intervention.
Primary Outcome
Change in HbA1C (%) at month 0 and month 6
Interventions
- DRUG Placebo
- DRUG sertraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
What the finished NCT00624013 record still lists
NCT00624013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00624013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00624013 about?
NCT00624013 is a clinical study titled "Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.". This proposed study will test the following hypothesis: Treating depression in Hispanics and African Americans with diabetes will improve their HbA1c and quality of life while on intervention and six months after intervention.
What is the current status of trial NCT00624013?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2006-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00624013?
The interventions under investigation include: Placebo (DRUG), sertraline (DRUG).
Who is sponsoring clinical trial NCT00624013?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00624013's enrollment target sits among peer trials
89 913th of 2000 higher than 1,085 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia